Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial
Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete r...
Uloženo v:
| Vydáno v: | The Lancet (British edition) Ročník 387; číslo 10014; s. 136 - 145 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
09.01.2016
Elsevier Limited |
| Témata: | |
| ISSN: | 0140-6736, 1474-547X, 1474-547X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention.
We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038.
Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575–758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82–1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04).
Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population.
Gilead Sciences, Menarini. |
|---|---|
| AbstractList | BACKGROUND: Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention.
METHODS: We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038.
FINDINGS: Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575-758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82-1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04).
INTERPRETATION: Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population.
FUNDING: Gilead Sciences, Menarini. Background Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention. Methods We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged greater than or equal to 18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with greater than or equal to 50% diameter stenosis in a coronary artery greater than or equal to 2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038. Findings Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575-758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0.95, 95% CI 0.82-1.10; p=0.48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0.04). Interpretation Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population. Funding Gilead Sciences, Menarini. Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention.BACKGROUNDIncomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention.We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038.METHODSWe performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038.Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575-758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82-1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04).FINDINGSBetween Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575-758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82-1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04).Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population.INTERPRETATIONRanolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population.Gilead Sciences, Menarini.FUNDINGGilead Sciences, Menarini. Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention. Methods We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged >=18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with >=50% diameter stenosis in a coronary artery >=2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presencevsabsence) and acute coronary syndrome presentation (acute coronary syndromevsnon-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered atClinicalTrials.gov, numberNCT01442038. Findings Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575-758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82-1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04). Interpretation Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population. Funding Gilead Sciences, Menarini. Summary Background Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention. Methods We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov , number NCT01442038. Findings Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575–758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82–1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04). Interpretation Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population. Funding Gilead Sciences, Menarini. Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events. We aimed to assess whether adjunctive anti-ischaemic pharmacotherapy with ranolazine would improve the prognosis of patients with incomplete revascularisation after percutaneous coronary intervention. We performed this multicentre, randomised, parallel-group, double-blind, placebo-controlled, event-driven trial at 245 centres in 15 countries in Europe, Israel, Russia, and the USA. Patients (aged ≥18 years) with a history of chronic angina with incomplete revascularisation after percutaneous coronary intervention (defined as one or more lesions with ≥50% diameter stenosis in a coronary artery ≥2 mm diameter) were randomly assigned (1:1), via an interactive web-based block randomisation system (block sizes of ten), to receive either twice-daily oral ranolazine 1000 mg or matching placebo. Randomisation was stratified by diabetes history (presence vs absence) and acute coronary syndrome presentation (acute coronary syndrome vs non-acute coronary syndrome). Study investigators, including all research teams, and patients were masked to treatment allocation. The primary endpoint was time to first occurrence of ischaemia-driven revascularisation or ischaemia-driven hospitalisation without revascularisation. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT01442038. Between Nov 3, 2011, and May 27, 2013, we randomly assigned 2651 patients to receive ranolazine (n=1332) or placebo (n=1319); 2604 (98%) patients comprised the full analysis set. After a median follow-up of 643 days (IQR 575–758), the composite primary endpoint occurred in 345 (26%) patients assigned to ranolazine and 364 (28%) patients assigned to placebo (hazard ratio 0·95, 95% CI 0·82–1·10; p=0·48). Incidence of ischaemia-driven revascularisation and ischaemia-driven hospitalisation did not differ significantly between groups. 189 (14%) patients in the ranolazine group and 137 (11%) patients in the placebo group discontinued study drug because of an adverse event (p=0·04). Ranolazine did not reduce the composite rate of ischaemia-driven revascularisation or hospitalisation without revascularisation in patients with a history of chronic angina who had incomplete revascularisation after percutaneous coronary intervention. Further studies are warranted to establish whether other treatment could be effective in improving the prognosis of high-risk patients in this population. Gilead Sciences, Menarini. |
| Author | Dressler, Ovidiu Osmukhina, Anna Ben-Yehuda, Ori Zurakowski, Aleksander Alexander, Karen P Ohman, E Magnus Weisz, Giora Shechter, Michael Stone, Gregg W Généreux, Philippe James, Stefan Iñiguez, Andres Farzaneh-Far, Ramin |
| Author_xml | – sequence: 1 givenname: Giora surname: Weisz fullname: Weisz, Giora email: weiszg@szmc.org.il organization: Shaare Zedek Medical Center, Jerusalem, Israel – sequence: 2 givenname: Philippe surname: Généreux fullname: Généreux, Philippe organization: Cardiovascular Research Foundation, New York, NY, USA – sequence: 3 givenname: Andres surname: Iñiguez fullname: Iñiguez, Andres organization: Hospital de Meixoeiro, Vigo, Spain – sequence: 4 givenname: Aleksander surname: Zurakowski fullname: Zurakowski, Aleksander organization: American Heart of Poland SA, Katowice, Poland – sequence: 5 givenname: Michael surname: Shechter fullname: Shechter, Michael organization: Chaim Sheba Medical Center, Tel Hashomer, Israel – sequence: 6 givenname: Karen P surname: Alexander fullname: Alexander, Karen P organization: Duke Clinical Research Institute and Duke University, Durham, NC, USA – sequence: 7 givenname: Ovidiu surname: Dressler fullname: Dressler, Ovidiu organization: Cardiovascular Research Foundation, New York, NY, USA – sequence: 8 givenname: Anna surname: Osmukhina fullname: Osmukhina, Anna organization: Gilead Sciences, Foster City, CA, USA – sequence: 9 givenname: Stefan surname: James fullname: James, Stefan organization: Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden – sequence: 10 givenname: E Magnus surname: Ohman fullname: Ohman, E Magnus organization: Duke Clinical Research Institute and Duke University, Durham, NC, USA – sequence: 11 givenname: Ori surname: Ben-Yehuda fullname: Ben-Yehuda, Ori organization: Cardiovascular Research Foundation, New York, NY, USA – sequence: 12 givenname: Ramin surname: Farzaneh-Far fullname: Farzaneh-Far, Ramin organization: Gilead Sciences, Foster City, CA, USA – sequence: 13 givenname: Gregg W surname: Stone fullname: Stone, Gregg W organization: New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26474810$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-278690$$DView record from Swedish Publication Index (Uppsala universitet) |
| BookMark | eNqNkmFr1DAYx4tM3G36EZSCb25w1aRN0lZRGefUg4Fy6vBdSNOnmplLapLemJ_Kj2juuk04kO1VSfN7fsmT53-Q7BlrIEkeY_QMI8yef0aYoIyVBZtieoQQoXXG7iUTTEqSUVJ-20smN8h-cuD9OYoUQ_RBsp-zSFUYTZI_S2GsFr-VgVSZtBdBgQk-vVDhR_wh7arXECB1sBZeDlo45SNjTSq6AC7twckhCAN28Km0zhrhLmNh3FtH0QacLhdnJ8vs03xx9CIV6WrQQcm452CWOmFau1Ie2lna2qHRkDVambjqtZDQ2EzaSFqtoU2DU0I_TO53Qnt4dPU9TL6-O_ky_5Cdfny_mB-fZpKRPGRVi2RRF01NREmQIBTLommqsmi6sqK1bAiu2iqnGFBBu0pKhLtS1oRJXHW4huIwmY1efwH90PDeqVVsjVuh-Ft1dsyt-86HgedlxWoU8emI987-GsAHHruSoPX4NByXjOCizqv8LmhesLrMN9anO-i5HZyJfUeKVjiv663wyRU1NCtob656PeUIvBwB6az3DjouVdhOMTihNMeIbzLFt5nim8BwTPk2U5zFarpTfX3AbXVvxjqIY1orcNzLGC4JrXIgA2-tutXwescgYziUFPonXIL_9xbc5xyNko0D061hI3j1f8EdLvAX09oNkA |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1007_s40119_020_00202_6 crossref_primary_10_3390_jcm11236891 crossref_primary_10_1016_j_ejphar_2022_174787 crossref_primary_10_1080_14656566_2017_1303483 crossref_primary_10_1016_j_jacc_2018_04_086 crossref_primary_10_1161_JAHA_116_003196 crossref_primary_10_1002_ccd_31142 crossref_primary_10_1002_ccd_26876 crossref_primary_10_1177_1074248416679733 crossref_primary_10_1007_s12325_020_01582_w crossref_primary_10_1016_j_ijcard_2016_10_102 crossref_primary_10_3390_jcm9072110 crossref_primary_10_1007_s10557_016_6681_2 crossref_primary_10_1016_j_ihj_2020_12_013 crossref_primary_10_1161_CIRCINTERVENTIONS_124_014054 crossref_primary_10_1093_eurheartj_ehv708 crossref_primary_10_1016_j_amjms_2023_12_001 crossref_primary_10_1016_j_cpcardiol_2020_100554 crossref_primary_10_1136_heartjnl_2018_314661 crossref_primary_10_1007_s10557_016_6662_5 crossref_primary_10_2217_fca_2021_0058 crossref_primary_10_1016_j_ihj_2016_11_320 crossref_primary_10_1136_openhrt_2018_000889 crossref_primary_10_1007_s11298_016_5747_6 crossref_primary_10_1038_s41569_021_00573_w crossref_primary_10_1016_j_pcad_2020_02_009 crossref_primary_10_1007_s12471_016_0862_2 crossref_primary_10_1093_eurheartj_ehaa820 crossref_primary_10_1177_1753944716636042 crossref_primary_10_1007_s40119_016_0081_3 crossref_primary_10_1007_s40119_021_00249_z crossref_primary_10_1016_j_hjc_2025_02_003 crossref_primary_10_1016_j_ijcard_2016_06_150 crossref_primary_10_1016_j_amjcard_2019_01_036 crossref_primary_10_1016_j_rec_2015_12_014 crossref_primary_10_1093_eurheartj_ehx764 crossref_primary_10_1093_eurheartj_ehz425 crossref_primary_10_1002_sim_10116 crossref_primary_10_1016_j_ejim_2021_08_003 crossref_primary_10_1016_j_jcin_2016_05_003 crossref_primary_10_1159_000444847 crossref_primary_10_1007_s12265_016_9702_4 crossref_primary_10_1080_13543784_2016_1254617 crossref_primary_10_1056_NEJMcp1502240 crossref_primary_10_1016_j_pcad_2016_04_003 crossref_primary_10_1016_j_carrev_2020_09_025 crossref_primary_10_1016_S0140_6736_20_31790_6 crossref_primary_10_1186_s13287_018_0969_z crossref_primary_10_2459_JCM_0000000000000442 crossref_primary_10_1177_2047487316648475 crossref_primary_10_1016_j_jacc_2017_12_068 crossref_primary_10_1161_CIRCRESAHA_118_314118 crossref_primary_10_1016_j_jcin_2016_03_042 crossref_primary_10_1007_s00059_016_4474_9 crossref_primary_10_3389_fcvm_2022_860059 crossref_primary_10_1111_eci_14331 crossref_primary_10_1007_s10557_021_07179_x crossref_primary_10_3390_medicina60010166 crossref_primary_10_1016_j_ahj_2021_06_013 crossref_primary_10_1080_14779072_2017_1270755 crossref_primary_10_1016_j_jacc_2017_02_056 crossref_primary_10_1093_eurheartj_suaa060 crossref_primary_10_1016_j_ahj_2018_12_015 crossref_primary_10_1093_eurheartj_ehv686 crossref_primary_10_1097_FJC_0000000000001436 crossref_primary_10_1161_CIRCINTERVENTIONS_123_012997 crossref_primary_10_1016_j_jacc_2017_03_532 crossref_primary_10_1161_JAHA_117_007007 |
| Cites_doi | 10.1056/NEJMoa1002358 10.1016/j.jcmg.2012.01.005 10.1002/clc.22425 10.1002/ccd.23006 10.1016/j.jacc.2014.12.038 10.1161/CIRCOUTCOMES.108.830091 10.1093/ejcts/ezr105 10.1161/CIRCULATIONAHA.106.612267 10.1001/jama.297.16.1775 10.1016/j.jacc.2012.03.010 10.1016/j.jacc.2003.11.045 10.1056/NEJMoa0807611 10.1016/j.jcin.2014.01.161 10.1016/j.ahj.2013.08.004 10.1161/CIRCULATIONAHA.111.084236 10.1016/S0735-1097(01)01785-5 10.1161/CIRCINTERVENTIONS.111.963058 10.1161/CIRCULATIONAHA.113.001803 10.1161/CIRCULATIONAHA.108.836601 10.1056/NEJMoa1408758 10.1016/j.jacc.2006.05.044 10.1016/j.jcin.2008.08.021 10.1161/CIRCULATIONAHA.111.069237 10.1016/j.yjmcc.2006.08.012 10.1056/NEJMoa1305520 10.1161/CIRCINTERVENTIONS.111.965509 10.1136/hrt.2005.078790 10.1001/jama.291.3.309 |
| ContentType | Journal Article |
| Contributor | Pocock, Stuart Hamm, Christian Ben-Yehuda, Ori Walker, Gennyne Katz, Amos Belle, Loic Zemanek, David Dauerman, Harold L Dzavik, Vladimir Jurgen, vom Dahl Mosseri, Morris Schuchlenz, Herwig Vrolix, Mathias Muyldermans, Luc Buszman, Pawel Licka, Manuela Antoniucci, David Généreux, Philippe Ohman, Magnus Rozenman, Yoseph Mortl, Deddo Mukherjee, Ashok Schampaert, Erick Ondrejcak, Roman Marx, Steven O Olbrich, Hans-Georg Hildick-Smith, David Nichols, Melissa Kala, Petr Carrie, Didier Berger, Rudolf Dogan, Ozgen Schulze-Waltrup, Norbert Steinwender, Clemens Alfonso, Fernando Budesinsky, Tomas Horak, Jan Friedrich, Guy Steg, Philippe Groch, Ladislav Stellbrink, Christoph Legrand, Victor Zhong, Ray Hang Mehta, Shamir Dorsch, Michael Danenberg, Haim Rodés-Cabau, Josep Kastner, Johannes Weisz, Giora Wong, Shing-Chiu Scott, Jenna Vered, Zvi Verheye, Stefan Hong, Mun Clayton, Tim Dressler, Ovidiu White, Harvey Frimerman, Aaron Turgeman, Yoav Widimsky, Petr Moellmann, Helge Stone, Gregg W Gersh, Bernard J Paris, Cedex Ince, Huseyin Gueta, Victor Williams, David O |
| Contributor_xml | – sequence: 1 givenname: Gregg W surname: Stone fullname: Stone, Gregg W – sequence: 2 givenname: Giora surname: Weisz fullname: Weisz, Giora – sequence: 3 givenname: Karen surname: Alexander fullname: Alexander, Karen – sequence: 4 givenname: Bernard surname: DeBruyne fullname: DeBruyne, Bernard – sequence: 5 givenname: Amir surname: Lerman fullname: Lerman, Amir – sequence: 6 givenname: Ehtisham surname: Mahmud fullname: Mahmud, Ehtisham – sequence: 7 givenname: Gilles surname: Montalescot fullname: Montalescot, Gilles – sequence: 8 givenname: Magnus surname: Ohman fullname: Ohman, Magnus – sequence: 9 givenname: Harvey surname: White fullname: White, Harvey – sequence: 10 givenname: Fernando surname: Alfonso fullname: Alfonso, Fernando – sequence: 11 givenname: David surname: Antoniucci fullname: Antoniucci, David – sequence: 12 givenname: Rudolf surname: Berger fullname: Berger, Rudolf – sequence: 13 givenname: Pawel surname: Buszman fullname: Buszman, Pawel – sequence: 14 givenname: Victor surname: Gueta fullname: Gueta, Victor – sequence: 15 givenname: Christian surname: Hamm fullname: Hamm, Christian – sequence: 16 givenname: David surname: Hildick-Smith fullname: Hildick-Smith, David – sequence: 17 givenname: Stefan surname: James fullname: James, Stefan – sequence: 18 givenname: Erick surname: Schampaert fullname: Schampaert, Erick – sequence: 19 givenname: Peter surname: Smith fullname: Smith, Peter – sequence: 20 givenname: Philippe surname: Steg fullname: Steg, Philippe – sequence: 21 givenname: Stefan surname: Veheye fullname: Veheye, Stefan – sequence: 22 givenname: Petr surname: Widimsky fullname: Widimsky, Petr – sequence: 23 givenname: Bernard J surname: Gersh fullname: Gersh, Bernard J – sequence: 24 givenname: Harold L surname: Dauerman fullname: Dauerman, Harold L – sequence: 25 givenname: Stuart surname: Pocock fullname: Pocock, Stuart – sequence: 26 givenname: David O surname: Williams fullname: Williams, David O – sequence: 27 givenname: David P surname: Faxon fullname: Faxon, David P – sequence: 28 givenname: David R surname: Holmes fullname: Holmes, David R – sequence: 29 givenname: Tim surname: Clayton fullname: Clayton, Tim – sequence: 30 givenname: Steven O surname: Marx fullname: Marx, Steven O – sequence: 31 givenname: Mun surname: Hong fullname: Hong, Mun – sequence: 32 givenname: Shing-Chiu surname: Wong fullname: Wong, Shing-Chiu – sequence: 33 givenname: Ozgen surname: Dogan fullname: Dogan, Ozgen – sequence: 34 givenname: Jesse surname: Weinberger fullname: Weinberger, Jesse – sequence: 35 givenname: Philippe surname: Généreux fullname: Généreux, Philippe – sequence: 36 givenname: Laura surname: LaSalle fullname: LaSalle, Laura – sequence: 37 givenname: Ori surname: Ben-Yehuda fullname: Ben-Yehuda, Ori – sequence: 38 givenname: Ovidiu surname: Dressler fullname: Dressler, Ovidiu – sequence: 39 givenname: Ray Hang surname: Zhong fullname: Zhong, Ray Hang – sequence: 40 givenname: Melissa surname: Nichols fullname: Nichols, Melissa – sequence: 41 givenname: Joe surname: Dizon fullname: Dizon, Joe – sequence: 42 givenname: Ramin surname: Farzaneh-Far fullname: Farzaneh-Far, Ramin – sequence: 43 givenname: Brian surname: McNabb fullname: McNabb, Brian – sequence: 44 givenname: Anna surname: Osmukhina fullname: Osmukhina, Anna – sequence: 45 givenname: Jenna surname: Scott fullname: Scott, Jenna – sequence: 46 givenname: Gennyne surname: Walker fullname: Walker, Gennyne – sequence: 47 givenname: Clemens surname: Steinwender fullname: Steinwender, Clemens – sequence: 48 givenname: Guy surname: Friedrich fullname: Friedrich, Guy – sequence: 49 givenname: Deddo surname: Mortl fullname: Mortl, Deddo – sequence: 50 givenname: Herwig surname: Schuchlenz fullname: Schuchlenz, Herwig – sequence: 51 givenname: Johannes surname: Kastner fullname: Kastner, Johannes – sequence: 52 givenname: Kurt surname: Huber fullname: Huber, Kurt – sequence: 53 givenname: Luc surname: Muyldermans fullname: Muyldermans, Luc – sequence: 54 givenname: Victor surname: Legrand fullname: Legrand, Victor – sequence: 55 givenname: John surname: Roosen fullname: Roosen, John – sequence: 56 givenname: Stefan surname: Verheye fullname: Verheye, Stefan – sequence: 57 givenname: Mathias surname: Vrolix fullname: Vrolix, Mathias – sequence: 58 givenname: André surname: Kokis fullname: Kokis, André – sequence: 59 givenname: Miche surname: Nguyen fullname: Nguyen, Miche – sequence: 60 givenname: Shamir surname: Mehta fullname: Mehta, Shamir – sequence: 61 givenname: Josep surname: Rodés-Cabau fullname: Rodés-Cabau, Josep – sequence: 62 givenname: Marc surname: Jolicoeur fullname: Jolicoeur, Marc – sequence: 63 givenname: Jaroslav surname: Hubacek fullname: Hubacek, Jaroslav – sequence: 64 givenname: Michael surname: Dorsch fullname: Dorsch, Michael – sequence: 65 givenname: Christopher surname: Buller fullname: Buller, Christopher – sequence: 66 givenname: Ashok surname: Mukherjee fullname: Mukherjee, Ashok – sequence: 67 givenname: Vladimir surname: Dzavik fullname: Dzavik, Vladimir – sequence: 68 givenname: Robert surname: Welsh fullname: Welsh, Robert – sequence: 69 givenname: Petr surname: Kala fullname: Kala, Petr – sequence: 70 givenname: Tomas surname: Budesinsky fullname: Budesinsky, Tomas – sequence: 71 givenname: Marcela surname: Skvarilová fullname: Skvarilová, Marcela – sequence: 72 givenname: Ladislav surname: Groch fullname: Groch, Ladislav – sequence: 73 givenname: David surname: Zemanek fullname: Zemanek, David – sequence: 74 givenname: Roman surname: Ondrejcak fullname: Ondrejcak, Roman – sequence: 75 givenname: David surname: Horak fullname: Horak, David – sequence: 76 givenname: Jan surname: Horak fullname: Horak, Jan – sequence: 77 givenname: Loic surname: Belle fullname: Belle, Loic – sequence: 78 givenname: Gery surname: Hannebicque fullname: Hannebicque, Gery – sequence: 79 givenname: Cedex surname: Paris fullname: Paris, Cedex – sequence: 80 givenname: Philippe Gabriel surname: Steg fullname: Steg, Philippe Gabriel – sequence: 81 givenname: Didier surname: Carrie fullname: Carrie, Didier – sequence: 82 givenname: Hans-Georg surname: Olbrich fullname: Olbrich, Hans-Georg – sequence: 83 givenname: Helge surname: Moellmann fullname: Moellmann, Helge – sequence: 84 givenname: vom Dahl surname: Jurgen fullname: Jurgen, vom Dahl – sequence: 85 givenname: Norbert surname: Schulze-Waltrup fullname: Schulze-Waltrup, Norbert – sequence: 86 givenname: Christoph surname: Stellbrink fullname: Stellbrink, Christoph – sequence: 87 givenname: Manuela surname: Licka fullname: Licka, Manuela – sequence: 88 givenname: Huseyin surname: Ince fullname: Ince, Huseyin – sequence: 89 givenname: Zvi surname: Vered fullname: Vered, Zvi – sequence: 90 givenname: Amos surname: Katz fullname: Katz, Amos – sequence: 91 givenname: Uri surname: Rosenschein fullname: Rosenschein, Uri – sequence: 92 givenname: Yoseph surname: Rozenman fullname: Rozenman, Yoseph – sequence: 93 givenname: Haim surname: Danenberg fullname: Danenberg, Haim – sequence: 94 givenname: Yoav surname: Turgeman fullname: Turgeman, Yoav – sequence: 95 givenname: Aaron surname: Frimerman fullname: Frimerman, Aaron – sequence: 96 givenname: Sara surname: Shimoni fullname: Shimoni, Sara – sequence: 97 givenname: Morris surname: Mosseri fullname: Mosseri, Morris – sequence: 98 givenname: Eugenia surname: Nikolsky fullname: Nikolsky, Eugenia |
| Copyright | 2016 Elsevier Ltd Elsevier Ltd Copyright © 2016 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 9, 2016 |
| Copyright_xml | – notice: 2016 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2016 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 9, 2016 |
| CorporateAuthor | RIVER-PCI investigators |
| CorporateAuthor_xml | – name: RIVER-PCI investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7T2 7X8 ADTPV AOWAS DF2 |
| DOI | 10.1016/S0140-6736(15)00459-6 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni) ProQuest Central (Alumni) One Sustainability ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials - QC ProQuest SciTech Premium Collection Natural Science Collection Biological Science Collection eLibrary ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea British Nursing Index (BNI) (1985 to Present) ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional ProQuest Biological Science Collection Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Psychology Database Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic SIRS Editorial Health and Safety Science Abstracts (Full archive) MEDLINE - Academic SwePub SwePub Articles SWEPUB Uppsala universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) Health & Safety Science Abstracts MEDLINE - Academic |
| DatabaseTitleList | Health & Safety Science Abstracts MEDLINE - Academic ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 145 |
| ExternalDocumentID | oai_DiVA_org_uu_278690 3926162571 26474810 10_1016_S0140_6736_15_00459_6 S0140673615004596 1_s2_0_S0140673615004596 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | INW, Russia USA Israel ANE, Europe |
| GeographicLocations_xml | – name: Israel – name: USA – name: INW, Russia – name: ANE, Europe |
| GrantInformation | Gilead Sciences, Menarini. |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7T2 7X8 PUEGO ADTPV AOWAS DF2 |
| ID | FETCH-LOGICAL-c642t-8d0c393b94a740a451c3bb873bf7859cb418d8251e035f8cc01f7c946c18f19e3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 84 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000368055500030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 1474-547X |
| IngestDate | Tue Nov 04 16:52:28 EST 2025 Sun Sep 28 10:21:01 EDT 2025 Tue Oct 07 09:52:12 EDT 2025 Sat Nov 29 14:25:55 EST 2025 Mon Jul 21 05:55:12 EDT 2025 Sat Nov 29 05:12:34 EST 2025 Tue Nov 18 21:31:37 EST 2025 Fri Feb 23 02:24:39 EST 2024 Sun Feb 23 10:19:17 EST 2025 Tue Oct 14 19:31:09 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10014 |
| Language | English |
| License | Copyright © 2016 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c642t-8d0c393b94a740a451c3bb873bf7859cb418d8251e035f8cc01f7c946c18f19e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 26474810 |
| PQID | 1758129982 |
| PQPubID | 40246 |
| PageCount | 10 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_uu_278690 proquest_miscellaneous_1764139282 proquest_miscellaneous_1762369720 proquest_journals_1758129982 pubmed_primary_26474810 crossref_citationtrail_10_1016_S0140_6736_15_00459_6 crossref_primary_10_1016_S0140_6736_15_00459_6 elsevier_sciencedirect_doi_10_1016_S0140_6736_15_00459_6 elsevier_clinicalkeyesjournals_1_s2_0_S0140673615004596 elsevier_clinicalkey_doi_10_1016_S0140_6736_15_00459_6 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-01-09 |
| PublicationDateYYYYMMDD | 2016-01-09 |
| PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-09 day: 09 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2016 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Weisz, Farzaneh-Far, Ben-Yehuda (bib25) 2013; 166 Farooq, Serruys, Bourantas (bib26) 2013; 128 Stone, Gratsiansky, Blokhin, Huang, Meng (bib20) 2006; 48 Gossl, Faxon, Bell, Holmes, Gersh (bib4) 2012; 5 Hannan, Wu, Walford (bib6) 2009; 2 Hussain, Philipp, Ducas (bib12) 2011; 78 Gershlick, Khan, Kelly (bib13) 2015; 65 Wald, Morris, Wald (bib14) 2013; 369 Hannan, Racz, Holmes (bib5) 2006; 113 Stone, Maehara, Lansky (bib24) 2011; 364 Chaitman, Skettino, Parker (bib18) 2004; 43 Nikolsky, Gruberg, Patil (bib11) 2004; 16 Wittes (bib30) 2009; 119 Belardinelli, Shryock, Fraser (bib17) 2006; 92 McPherson, Maehara, Weisz (bib15) 2012; 5 Genereux, Palmerini, Caixeta (bib3) 2012; 59 Rosner, Kirtane, Genereux (bib2) 2012; 125 Mancini, Bates, Maron (bib9) 2009; 2 Wu, Dyer, King (bib7) 2011; 4 Gutierrez, Karwatowska-Prokopczuk, Murphy (bib22) 2015; 38 Zellweger, Fahrni, Ritter (bib23) 2014; 7 Morrow, Scirica, Karwatowska-Prokopczuk (bib21) 2007; 297 Chaitman, Pepine, Parker (bib19) 2004; 291 (bib31) 2013 De Bruyne, Fearon, Pijls (bib28) 2014; 371 Vieira, Hueb, Gersh (bib10) 2012; 126 van den Brand, Rensing, Morel (bib8) 2002; 39 Mozaffarian, Benjamin, Go (bib1) 2015; 131 Tonino, De Bruyne, Pijls (bib27) 2009; 360 Head, Mack, Holmes (bib16) 2012; 41 Fraser, Belardinelli, Wang, Light, McVeigh, Clanachan (bib29) 2006; 41 Stone (10.1016/S0140-6736(15)00459-6_bib24) 2011; 364 Mozaffarian (10.1016/S0140-6736(15)00459-6_bib1) 2015; 131 Gossl (10.1016/S0140-6736(15)00459-6_bib4) 2012; 5 Wald (10.1016/S0140-6736(15)00459-6_bib14) 2013; 369 Hussain (10.1016/S0140-6736(15)00459-6_bib12) 2011; 78 Farooq (10.1016/S0140-6736(15)00459-6_bib26) 2013; 128 Genereux (10.1016/S0140-6736(15)00459-6_bib3) 2012; 59 Stone (10.1016/S0140-6736(15)00459-6_bib20) 2006; 48 Weisz (10.1016/S0140-6736(15)00459-6_bib25) 2013; 166 McPherson (10.1016/S0140-6736(15)00459-6_bib15) 2012; 5 Head (10.1016/S0140-6736(15)00459-6_bib16) 2012; 41 Wittes (10.1016/S0140-6736(15)00459-6_bib30) 2009; 119 Hannan (10.1016/S0140-6736(15)00459-6_bib5) 2006; 113 Mancini (10.1016/S0140-6736(15)00459-6_bib9) 2009; 2 Chaitman (10.1016/S0140-6736(15)00459-6_bib19) 2004; 291 Zellweger (10.1016/S0140-6736(15)00459-6_bib23) 2014; 7 Morrow (10.1016/S0140-6736(15)00459-6_bib21) 2007; 297 Nikolsky (10.1016/S0140-6736(15)00459-6_bib11) 2004; 16 Wu (10.1016/S0140-6736(15)00459-6_bib7) 2011; 4 Rosner (10.1016/S0140-6736(15)00459-6_bib2) 2012; 125 Tonino (10.1016/S0140-6736(15)00459-6_bib27) 2009; 360 De Bruyne (10.1016/S0140-6736(15)00459-6_bib28) 2014; 371 Gutierrez (10.1016/S0140-6736(15)00459-6_bib22) 2015; 38 Vieira (10.1016/S0140-6736(15)00459-6_bib10) 2012; 126 Fraser (10.1016/S0140-6736(15)00459-6_bib29) 2006; 41 van den Brand (10.1016/S0140-6736(15)00459-6_bib8) 2002; 39 Belardinelli (10.1016/S0140-6736(15)00459-6_bib17) 2006; 92 Hannan (10.1016/S0140-6736(15)00459-6_bib6) 2009; 2 Gershlick (10.1016/S0140-6736(15)00459-6_bib13) 2015; 65 Chaitman (10.1016/S0140-6736(15)00459-6_bib18) 2004; 43 26474812 - Lancet. 2016 Jan 9;387(10014):100-2 |
| References_xml | – volume: 291 start-page: 309 year: 2004 end-page: 316 ident: bib19 article-title: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial publication-title: JAMA – year: 2013 ident: bib31 article-title: Ranolazine prescribing information: 8.5 geriatric use – volume: 166 start-page: 953 year: 2013 end-page: 959 ident: bib25 article-title: Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial publication-title: Am Heart J – volume: 360 start-page: 213 year: 2009 end-page: 224 ident: bib27 article-title: Fractional flow reserve versus angiography for guiding percutaneous coronary intervention publication-title: N Engl J Med – volume: 43 start-page: 1375 year: 2004 end-page: 1382 ident: bib18 article-title: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina publication-title: J Am Coll Cardiol – volume: 369 start-page: 1115 year: 2013 end-page: 1123 ident: bib14 article-title: Randomized trial of preventive angioplasty in myocardial infarction publication-title: N Engl J Med – volume: 364 start-page: 226 year: 2011 end-page: 235 ident: bib24 article-title: A prospective natural-history study of coronary atherosclerosis publication-title: N Engl J Med – volume: 16 start-page: 102 year: 2004 end-page: 106 ident: bib11 article-title: Percutaneous coronary interventions in diabetic patients: is complete revascularization important? publication-title: J Invasive Cardiol – volume: 7 start-page: 615 year: 2014 end-page: 621 ident: bib23 article-title: Prognostic value of “routine” cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitats Trial) LATE IMAGING study publication-title: JACC Cardiovasc Interv – volume: 128 start-page: 141 year: 2013 end-page: 151 ident: bib26 article-title: Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score publication-title: Circulation – volume: 5 start-page: 597 year: 2012 end-page: 604 ident: bib4 article-title: Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease publication-title: Circ Cardiovasc Interv – volume: 48 start-page: 566 year: 2006 end-page: 575 ident: bib20 article-title: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial publication-title: J Am Coll Cardiol – volume: 41 start-page: 1031 year: 2006 end-page: 1038 ident: bib29 article-title: Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts publication-title: J Mol Cell Cardiol – volume: 297 start-page: 1775 year: 2007 end-page: 1783 ident: bib21 article-title: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial publication-title: JAMA – volume: 39 start-page: 559 year: 2002 end-page: 564 ident: bib8 article-title: The effect of completeness of revascularization on event-free survival at one year in the ARTS trial publication-title: J Am Coll Cardiol – volume: 2 start-page: 17 year: 2009 end-page: 25 ident: bib6 article-title: Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes publication-title: JACC Cardiovasc Interven – volume: 125 start-page: 2613 year: 2012 end-page: 2620 ident: bib2 article-title: Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial publication-title: Circulation – volume: 65 start-page: 963 year: 2015 end-page: 972 ident: bib13 article-title: Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial publication-title: J Am Coll Cardiol – volume: 41 start-page: 535 year: 2012 end-page: 541 ident: bib16 article-title: Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data publication-title: Eur J Cardiothorac Surg – volume: 126 start-page: S158 year: 2012 end-page: S163 ident: bib10 article-title: Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial publication-title: Circulation – volume: 92 start-page: iv6 year: 2006 end-page: i14 ident: bib17 article-title: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine publication-title: Heart – volume: 5 start-page: S76 year: 2012 end-page: S85 ident: bib15 article-title: Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention publication-title: JACC Cardiovasc Imaging – volume: 59 start-page: 2165 year: 2012 end-page: 2174 ident: bib3 article-title: Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score publication-title: J Am Coll Cardiol – volume: 2 start-page: 320 year: 2009 end-page: 327 ident: bib9 article-title: Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial publication-title: Circ Cardiovasc Qual Outcomes – volume: 119 start-page: 912 year: 2009 end-page: 915 ident: bib30 article-title: On looking at subgroups publication-title: Circulation – volume: 371 start-page: 1208 year: 2014 end-page: 1217 ident: bib28 article-title: Fractional flow reserve-guided PCI for stable coronary artery disease publication-title: N Engl J Med – volume: 131 start-page: e29 year: 2015 end-page: 322 ident: bib1 article-title: Heart disease and stroke statistics—2015 update: a report from the American Heart Association publication-title: Circulation – volume: 4 start-page: 413 year: 2011 end-page: 421 ident: bib7 article-title: Impact of incomplete revascularization on long-term mortality after coronary stenting publication-title: Circ Cardiovasc Interven – volume: 113 start-page: 2406 year: 2006 end-page: 2412 ident: bib5 article-title: Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era publication-title: Circulation – volume: 78 start-page: 540 year: 2011 end-page: 548 ident: bib12 article-title: The ability to achieve complete revascularization is associated with improved in-hospital survival in cardiogenic shock due to myocardial infarction: Manitoba cardiogenic SHOCK Registry investigators publication-title: Catheter Cardiovasc Interv – volume: 38 start-page: 469 year: 2015 end-page: 475 ident: bib22 article-title: Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial publication-title: Clin Cardiology – volume: 364 start-page: 226 year: 2011 ident: 10.1016/S0140-6736(15)00459-6_bib24 article-title: A prospective natural-history study of coronary atherosclerosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1002358 – volume: 5 start-page: S76 year: 2012 ident: 10.1016/S0140-6736(15)00459-6_bib15 article-title: Residual plaque burden in patients with acute coronary syndromes after successful percutaneous coronary intervention publication-title: JACC Cardiovasc Imaging doi: 10.1016/j.jcmg.2012.01.005 – volume: 16 start-page: 102 year: 2004 ident: 10.1016/S0140-6736(15)00459-6_bib11 article-title: Percutaneous coronary interventions in diabetic patients: is complete revascularization important? publication-title: J Invasive Cardiol – volume: 38 start-page: 469 year: 2015 ident: 10.1016/S0140-6736(15)00459-6_bib22 article-title: Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial publication-title: Clin Cardiology doi: 10.1002/clc.22425 – volume: 78 start-page: 540 year: 2011 ident: 10.1016/S0140-6736(15)00459-6_bib12 article-title: The ability to achieve complete revascularization is associated with improved in-hospital survival in cardiogenic shock due to myocardial infarction: Manitoba cardiogenic SHOCK Registry investigators publication-title: Catheter Cardiovasc Interv doi: 10.1002/ccd.23006 – volume: 65 start-page: 963 year: 2015 ident: 10.1016/S0140-6736(15)00459-6_bib13 article-title: Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2014.12.038 – volume: 2 start-page: 320 year: 2009 ident: 10.1016/S0140-6736(15)00459-6_bib9 article-title: Quantitative results of baseline angiography and percutaneous coronary intervention in the COURAGE trial publication-title: Circ Cardiovasc Qual Outcomes doi: 10.1161/CIRCOUTCOMES.108.830091 – volume: 41 start-page: 535 year: 2012 ident: 10.1016/S0140-6736(15)00459-6_bib16 article-title: Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data publication-title: Eur J Cardiothorac Surg doi: 10.1093/ejcts/ezr105 – volume: 113 start-page: 2406 year: 2006 ident: 10.1016/S0140-6736(15)00459-6_bib5 article-title: Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.106.612267 – volume: 297 start-page: 1775 year: 2007 ident: 10.1016/S0140-6736(15)00459-6_bib21 article-title: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial publication-title: JAMA doi: 10.1001/jama.297.16.1775 – volume: 59 start-page: 2165 year: 2012 ident: 10.1016/S0140-6736(15)00459-6_bib3 article-title: Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2012.03.010 – volume: 131 start-page: e29 year: 2015 ident: 10.1016/S0140-6736(15)00459-6_bib1 article-title: Heart disease and stroke statistics—2015 update: a report from the American Heart Association publication-title: Circulation – volume: 43 start-page: 1375 year: 2004 ident: 10.1016/S0140-6736(15)00459-6_bib18 article-title: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2003.11.045 – volume: 360 start-page: 213 year: 2009 ident: 10.1016/S0140-6736(15)00459-6_bib27 article-title: Fractional flow reserve versus angiography for guiding percutaneous coronary intervention publication-title: N Engl J Med doi: 10.1056/NEJMoa0807611 – volume: 7 start-page: 615 year: 2014 ident: 10.1016/S0140-6736(15)00459-6_bib23 article-title: Prognostic value of “routine” cardiac stress imaging 5 years after percutaneous coronary intervention: the prospective long-term observational BASKET (Basel Stent Kosteneffektivitats Trial) LATE IMAGING study publication-title: JACC Cardiovasc Interv doi: 10.1016/j.jcin.2014.01.161 – volume: 166 start-page: 953 year: 2013 ident: 10.1016/S0140-6736(15)00459-6_bib25 article-title: Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial publication-title: Am Heart J doi: 10.1016/j.ahj.2013.08.004 – volume: 126 start-page: S158 year: 2012 ident: 10.1016/S0140-6736(15)00459-6_bib10 article-title: Effect of complete revascularization on 10-year survival of patients with stable multivessel coronary artery disease: MASS II trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.084236 – volume: 39 start-page: 559 year: 2002 ident: 10.1016/S0140-6736(15)00459-6_bib8 article-title: The effect of completeness of revascularization on event-free survival at one year in the ARTS trial publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(01)01785-5 – volume: 4 start-page: 413 year: 2011 ident: 10.1016/S0140-6736(15)00459-6_bib7 article-title: Impact of incomplete revascularization on long-term mortality after coronary stenting publication-title: Circ Cardiovasc Interven doi: 10.1161/CIRCINTERVENTIONS.111.963058 – volume: 128 start-page: 141 year: 2013 ident: 10.1016/S0140-6736(15)00459-6_bib26 article-title: Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.001803 – volume: 119 start-page: 912 year: 2009 ident: 10.1016/S0140-6736(15)00459-6_bib30 article-title: On looking at subgroups publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.108.836601 – volume: 371 start-page: 1208 year: 2014 ident: 10.1016/S0140-6736(15)00459-6_bib28 article-title: Fractional flow reserve-guided PCI for stable coronary artery disease publication-title: N Engl J Med doi: 10.1056/NEJMoa1408758 – volume: 48 start-page: 566 year: 2006 ident: 10.1016/S0140-6736(15)00459-6_bib20 article-title: Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2006.05.044 – volume: 2 start-page: 17 year: 2009 ident: 10.1016/S0140-6736(15)00459-6_bib6 article-title: Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes publication-title: JACC Cardiovasc Interven doi: 10.1016/j.jcin.2008.08.021 – volume: 125 start-page: 2613 year: 2012 ident: 10.1016/S0140-6736(15)00459-6_bib2 article-title: Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.069237 – volume: 41 start-page: 1031 year: 2006 ident: 10.1016/S0140-6736(15)00459-6_bib29 article-title: Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2006.08.012 – volume: 369 start-page: 1115 year: 2013 ident: 10.1016/S0140-6736(15)00459-6_bib14 article-title: Randomized trial of preventive angioplasty in myocardial infarction publication-title: N Engl J Med doi: 10.1056/NEJMoa1305520 – volume: 5 start-page: 597 year: 2012 ident: 10.1016/S0140-6736(15)00459-6_bib4 article-title: Complete versus incomplete revascularization with coronary artery bypass graft or percutaneous intervention in stable coronary artery disease publication-title: Circ Cardiovasc Interv doi: 10.1161/CIRCINTERVENTIONS.111.965509 – volume: 92 start-page: iv6 year: 2006 ident: 10.1016/S0140-6736(15)00459-6_bib17 article-title: Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine publication-title: Heart doi: 10.1136/hrt.2005.078790 – volume: 291 start-page: 309 year: 2004 ident: 10.1016/S0140-6736(15)00459-6_bib19 article-title: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.291.3.309 – reference: 26474812 - Lancet. 2016 Jan 9;387(10014):100-2 |
| SSID | ssj0004605 |
| Score | 2.4884262 |
| Snippet | Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse cardiovascular events.... Summary Background Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse... Background Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse... BACKGROUND: Incomplete revascularisation is common after percutaneous coronary intervention and is associated with increased mortality and adverse... |
| SourceID | swepub proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 136 |
| SubjectTerms | Aged Angina pectoris Angina Pectoris - therapy Angioplasty Cardiology Coronary Artery Disease - therapy Coronary Stenosis - therapy Double-Blind Method Drug therapy Female Heart attacks Hospitalization - statistics & numerical data Humans Internal Medicine Intervention Ischemic Attack, Transient - epidemiology Male Medical prognosis Myocardial Infarction - epidemiology Myocardial Ischemia - epidemiology Myocardial Ischemia - therapy Myocardial Revascularization - statistics & numerical data Percutaneous Coronary Intervention Ranolazine - therapeutic use Sodium Channel Blockers - therapeutic use Stroke - epidemiology |
| Title | Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673615004596 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673615004596 https://dx.doi.org/10.1016/S0140-6736(15)00459-6 https://www.ncbi.nlm.nih.gov/pubmed/26474810 https://www.proquest.com/docview/1758129982 https://www.proquest.com/docview/1762369720 https://www.proquest.com/docview/1764139282 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-278690 |
| Volume | 387 |
| WOSCitedRecordID | wos000368055500030&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250908 omitProxy: false ssIdentifier: ssj0004605 issn: 1474-547X databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLbYhhAv3C-FURkJpE2aWS5ObPOCRunEJFqqMqq-WbHjoEpVU5IGiX_FT-TYuQxB2ZB4OVKafE3anJzz2fl8DkIvYgiAkIl8whOlCY2EIiIWPklYCJCQJnUvgtkHNh7z-VxMmgm3spFVtjHRBeo013aO_BjSHOQiGBwEb9Zfie0aZd-uNi00dtCerZIQOuneZNu6SCdxv1jBc_yp-_DAjw4tsREk_ltu-pN7_lZY1CWj09v_-zPuoFsNDcUntd_cRdfM6h66MWpetN9HP6bJCga9tvQ0XqxwU321xHbaFtuCDrao8MbgwrRS1kYWhF3Tcbw2ha6Ad5q8KrG2VRKS4jte_CKwxAfTs9lwSiaDs8PXOMFO2eikouYIQwJNc_BAkx7hNK_U0hAFfBi2nIZM5aSR2C9Nil3jkQfo8-nwfPCeNM0diIYhz4bw1NOhCJWgCaNeQiNfh0pxFqqM8UhoRX2e2nW1xgujjGvt-RnTgsba55kvTPgQ7a7ylXmMsBfpQGQGhkYpp0miOA1p4GWKJSaDAaDqIdreVqmbyue2AcdSbpG4-ZF03iDjHnrVwdZ16Y-rAHHrM7Jd1wqRWEJyugrItgFN2cSTUvqyDKRXoy0YaLyFApJ3yIYy1VToX06633qovDhP55499LzbDffbvkaqnQaOAcocCxZ4lx4D7EgE9nse1Y9M9x8CBWeU-4B-WT9D3R5b6vzdYnYi8-KLrCoZMNsv7cnlF_oU3QQSW0-LiX20uykq8wxd1982i7Loox02nVk7Z85ysHzg99He2-F4MoWtkVfbc2uDkbMfnZ30XTj5Ccu6blk |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90thgJGYtEkzy8WJbSSEpl20am01la7am4kdB1WqmpI0oP0pxE_kOLchKBsve-CxTb4kcnx8vuN85xyE3oSwAIIncgmPlCY0EIqIULgkYj5AfBpVvQjGPTYY8NNTcbyCvje5MFZW2ayJ5UIdp9rukW-DmwNfBMGB92H-hdiuUfbratNCo5oWR-bsG4Rs-fvuHrzfdc872B_tHpK6qwDRwLUXhMeO9oWvBI0YdSIauNpXijNfJYwHQivq8tgmdBrHDxKuteMmTAsaapcnrjA-XPcaum7r6lkJYd8ZLcvDLCX15xlD2x_bPzfcYNMSKUHCv_nCP7nub4VMS-d3cPd_G7Z76E5Ns_FOZRf30YqZPUA3-7WQ4CH6MYxmENTb0tp4MsN1ddkc221pbAtW2KLJC4Mz00h1a9kTLpuq47nJdAG82qRFjrWtAhFlZ3jyi4AUbwy74_0hOd7tbr7DES6Vm6UU1mxhIAhxChZm4i0cp4WaGqKA78OvUiOnUlKnEExNjMvGKo_QyZWM12O0Oktn5inCTqA9kRgI_WJOo0hx6lPPSRSLTAIBruog2kwjqevK7rbByFQukfC5gSxnnww76G0Lm1elTS4DhM0clU3eLngaCc73MiBbBjR5vV7m0pW5J50KbcEQplgoIHmLrClhRfX-5aZrjUXI8_u05tBBr9vD8L7tZ7Jq0sA5EBKEgnnOhecA-xOevc6TykTbMYQQg1HuAnq9stn2iC3lvjcZ78g0-yyLQnrM9oN7dvGDvkK3Dkf9nux1B0fP0W0g7NUWoFhDq4usMC_QDf11Mcmzl-VihNGnqzbjnwWKwBE |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQBMv3C-FAUZi0ibNNE6cxEZCaGpXUW1UVYFqbyZ2HFSpakrSgPaveObXcZzbEJSNlz3w2CZfEjnn6nznHIReBGAAwRNRwiOlCfOFIiIQlEShBxCPRdUsgulxOBrxkxMx3kA_mloYS6tsbGJpqONU2z3yLrg58EWQHLjdpKZFjPuDN8svxE6Qsl9am3EalYgcmdNvkL7lr4d9eNc7rjs4_NB7S-oJA0RD3L0iPHa0JzwlWBQyJ2I-1Z5SPPRUEnJfaMUoj21xp3E8P-FaOzQJtWCBpjyhwnhw3SvoauiBFNsq9R5dV5NZ0uvPqoe679s_d6m_Z4MqQYK_-cU_497fmpqWjnBw839ewlvoRh1-44NKX26jDbO4g7be1QSDu-j7JFpAsm9bbuPZAtddZ3Nst6uxbWRhmymvDM5MQ-Gt6VC4HLaOlybTBcTbJi1yrG13iCg7xbNfiKV4dzKcHk7IuDfce4UjXDI6S4qs2ccQOMQpaJ6J93GcFmpuiII8AH6V3DmVkrq0YG5iXA5cuYc-Xsp63Uebi3RhHiLs-NoViYGUMOYsihRnHnOdRIWRSSDxVR3EGpGSuu74bgePzOUaah_1ZSmJMuigly1sWbU8uQgQNPIqm3pe8EASnPJFwHAd0OS1Hc0llbkrnQptwZC-WCggeYusQ8UqBPyXm2432iHP7tOqRgc9bw_D-7afzyqhgXMgVQhE6DrnngNRoXDtdR5U6tquIaQeIeMU0DuV_rZHbIv3_mx6INPssywK6YZ2Ttyj8x_0GdoC7ZXHw9HRY3Qd4vhqZ1Bso81VVpgn6Jr-uprl2dPSLmH06bK1-CcY_ciP |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ranolazine+in+patients+with+incomplete+revascularisation+after+percutaneous+coronary+intervention+%28RIVER-PCI%29%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=Weisz%2C+Giora%2C+Dr&rft.au=G%C3%A9n%C3%A9reux%2C+Philippe%2C+MD&rft.au=I%C3%B1iguez%2C+Andres%2C+MD&rft.au=Zurakowski%2C+Aleksander%2C+MD&rft.date=2016-01-09&rft.issn=0140-6736&rft.volume=387&rft.issue=10014&rft.spage=136&rft.epage=145&rft_id=info:doi/10.1016%2FS0140-6736%2815%2900459-6&rft.externalDBID=ECK1-s2.0-S0140673615004596&rft.externalDocID=1_s2_0_S0140673615004596 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01406736%2FS0140673616X00025%2Fcov150h.gif |